These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: 3TC approval may revive AZT's appeal.
    Author: Vazquez E.
    Journal: Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136.
    Abstract:
    The Food and Drug Administration (FDA) approved 3TC (Epivir), a nucleoside analogue, for use in combination with AZT in patients with advanced HIV disease. Other nucleoside analogues, such as ddI, ddC, and d4T, have been approved for use only after AZT monotherapy fails. Glaxo Wellcome is conducting two studies to prove that 3TC increases survival or provides clinical benefit. One study is for adults with prior antiretroviral therapy, the other is for children who are antiretroviral naive. All subjects must have advanced HIV-disease. Consumer groups warn that 3TC's high cost may prevent it from being added to AIDS Drug Reimbursement Programs.
    [Abstract] [Full Text] [Related] [New Search]